These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 2256199)
1. Phase II study with high doses of epirubicin in patients with advanced rectal cancer. Alberola V; García Conde J; Jimeno J; Fernandez Martos C; Herranz C; Macheng I; Centelles M; Sánchez J Tumori; 1990 Oct; 76(5):503-4. PubMed ID: 2256199 [TBL] [Abstract][Full Text] [Related]
2. Epirubicin in rectal cancer. Moreno Nogueira J; Murillo E; Duque A; Jimeno J; Iglesias L; Romero F; Codes M; Bona X Chemioterapia; 1988 Jun; 7(3):189-94. PubMed ID: 3168075 [TBL] [Abstract][Full Text] [Related]
3. A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. Molinaro P; Lafleur F; Blum RH Am J Clin Oncol; 1989 Aug; 12(4):332-4. PubMed ID: 2667324 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of epirubicin in advanced soft tissue sarcoma. Chevallier B; Montcuquet P; Fachini T; Nguyen Bui B; Kerbrat P; Bastit P; Vo Van ML Bull Cancer; 1990; 77(10):991-5. PubMed ID: 2249019 [TBL] [Abstract][Full Text] [Related]
5. Single agent epirubicin in squamous cell cervical cancer. A phase II trial. Calero F; Rodriguez-Escudero F; Jimeno J; Mendaña J; Iglesias J; Murillo F; Ugalde F; Armas A; Rementeria A; Asins J Acta Oncol; 1991; 30(3):325-7. PubMed ID: 2036241 [TBL] [Abstract][Full Text] [Related]
6. Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO). Calero F; Asins-Codoñer E; Jimeno J; Rodriguez Escudero F; Mendaña J; Iglesias J; Matía F; Armas A; Díaz-Castellanos R; Garzón J Eur J Cancer; 1991; 27(7):864-6. PubMed ID: 1834118 [TBL] [Abstract][Full Text] [Related]
7. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. Quoix EA; Giaccone G; Jassem J; Karnicka H; Wiatr E; Cortes-Funes H; Roozendaal KJ; Kirkpatrick A; Evrard D; van Zandwijk N Eur J Cancer; 1992; 28A(10):1667-70. PubMed ID: 1327019 [TBL] [Abstract][Full Text] [Related]
8. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Nielsen D; Dombernowsky P; Larsen SK; Hansen OP; Skovsgaard T Cancer Chemother Pharmacol; 2000; 46(6):459-66. PubMed ID: 11138459 [TBL] [Abstract][Full Text] [Related]
10. Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Nielsen D; Dombernowsky P; Skovsgaard T; Jensen J; Andersen E; Engelholm SA; Hansen M Ann Oncol; 1990 Jul; 1(4):275-80. PubMed ID: 2265137 [TBL] [Abstract][Full Text] [Related]
11. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000 [TBL] [Abstract][Full Text] [Related]
12. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer. Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. Pyrhönen SO; Kouri MO Eur J Cancer; 1992; 28A(11):1828-32. PubMed ID: 1389520 [TBL] [Abstract][Full Text] [Related]
14. Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. Chevallier B; Leyvraz S; Olivier JP; Fargeot P; Facchini T; Vo Van ML Cancer Invest; 1993; 11(2):135-9. PubMed ID: 8462014 [TBL] [Abstract][Full Text] [Related]
15. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study. Fountzilas G; Skarlos D; Pavlidis NA; Makrantonakis P; Tsavaris N; Kalogera-Fountzila A; Giannakakis T; Beer M; Kosmidis P Tumori; 1991 Jun; 77(3):232-6. PubMed ID: 1862551 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of high-dose epirubicin in non-small cell lung cancer. Wils J; Utama I; Sala L; Smeets J; Riva A Eur J Cancer; 1990; 26(11-12):1140-1. PubMed ID: 1963545 [TBL] [Abstract][Full Text] [Related]
17. Sequential administration of epirubicin and paclitaxel for advanced breast cancer. A phase I randomised trial. Focan C; Graas MP; Beauduin M; Canon JL; Salmon JP; Jerusalem G; Focan-Henrard D; Lobelle JP; Schallier D Anticancer Res; 2005; 25(2B):1211-7. PubMed ID: 15865068 [TBL] [Abstract][Full Text] [Related]
18. High-dose epirubicin for untreated patients with advanced tumours: a phase I study. Martoni A; Melotti B; Guaraldi M; Pacciarini MA; Riva A; Pannuti F Eur J Cancer; 1990; 26(11-12):1137-40. PubMed ID: 1963544 [TBL] [Abstract][Full Text] [Related]
19. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Holdener EE; Hansen HH; Høst H; Bruntsch U; Cavalli F; Renard J; Pinedo HM; Rozencweig M Invest New Drugs; 1985; 3(1):63-6. PubMed ID: 3857219 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]